740207
Last Update Posted: 2011-05-09
Recruiting has ended
All Genders accepted | 18 Years + |
33 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.
Eligibility
Relevant conditions:
Peripheral Arterial Occlusive Disease
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov